A5044746312- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Metastasis and carcinoma case studies
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- HIV/AIDS drug development and treatment
- Histone Deacetylase Inhibitors Research
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Nutrition and Health in Aging
- Bladder and Urothelial Cancer Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Cytomegalovirus and herpesvirus research
- Nanoplatforms for cancer theranostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Bariatric Surgery and Outcomes
- Neuroendocrine Tumor Research Advances
University of Minnesota
2018-2022
Rutgers, The State University of New Jersey
2015-2017
Rutgers New Jersey Medical School
2015-2017
Shanghai Pulmonary Hospital
2017
Tongji University
2017
The authors' previous study demonstrated that the B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients non-small cell lung cancer (NSCLC) EGFR mutations. objective of current investigate impact Bim among anaplastic lymphoma (ALK)-positive or ROS proto-oncogene 1, (ROS1)-positive NSCLC who were treated crizotinib.A total 55...
Data on the clinical activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer (NSCLC) and uncommon EGFR mutations remain insufficient. This study aimed to investigate effect first-line EGFR-TKIs or platinum-based chemotherapy NSCLC mutations.We retrospectively enrolled 504 EGFR-mutant NSCLC. The characteristics treatment outcomes were collected compared between common NSCLC.Seventy (13.9%) harboring included. Thirty...
BackgroundIn solid tumours, antibiotic use during immune checkpoint inhibitor (ICI) treatment is associated with shorter survival. Following allogeneic haematopoietic cell transplantation (allo-HCT), antibiotic-induced gut microbiome alterations are risk of relapse and mortality. These findings suggest that the microbiota can modulate antitumour response across tumour types, though it not clear if impact on outcomes specific to therapy. An important limitation previous studies analysis...
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of advanced-stage non-small-cell lung cancer (NSCLC) and small-cell (SCLC). The aim this study was to evaluate effectiveness tolerance ICIs in a real-world patient population investigate predictive factors associated with survival outcomes.Medical records patients advanced who started ICI monotherapy were reviewed for data collection. Treatment outcomes included objective response rate, progression-free (PFS), overall...
Escalating doses of bortezomib with high-dose melphalan was evaluated as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients relapsed or refractory multiple myeloma (MM). MM less than partial remission (PR) (or 50% reduction) compared to their pretransplantation paraprotein parameters after prior ASCT conditioning, who were relapse transplantation, eligible study. Bortezomib dose escalated steps 1, 1.3, and 1.6 mg/m2 (3 × 3 design) on days −4 −1 before 200...
e19522 Background: Panobinostat (pano) is a pan histone de-acetylatase inhibitor (HDAC-i) approved by the FDA for use with bortezomib (btz) and dexamethasone (dex) patients multiple myeloma (MM) who have had ≥2 prior lines of therapy including both btz an immunomodulatory agent (IMiD). The goal this retrospective study to evaluate efficacy safety pano in combination variety agents as would be utilized real world management relapsed/refractory (RR) MM. Methods: Between February 2015 July...
e19062 Background: NSCLC patients (pts) develop brain metastasis (BM) early, usually within 2 years of diagnosis. BM are an important cause morbidity and mortality, the study prognostic factors is vital in creating measures to prevent BM. The aim this was evaluate value certain clinical characteristics development NSCLC. Methods: We retrospectively analyzed all pts diagnosed with at our institution between 2000 2013. Demographics, tumor metastatic patterns were studied. Median follow up 45...
2529 Background: Early phase clinical trials (EPCT) evaluate the potential benefits of new regimens and help guide care oncology patients (pts).The inclusion/exclusion criteria in EPCT are usually rigorous may exclude many pts commonly seen practice. Our objective was to study most common comorbidities excluded Methods: ClinicalTrials.gov queried December 1st 2015. We reviewed eligibility 1114 I/II including: age, organ function comorbidities. Logistic regressions were completed exclusion...
e21533 Background: We aimed to evaluate post-gastrectomy outcomes in patients (pts) age ≥ 75 using the Nationwide Inpatient Sample (NIS), as population based data elderly pts are needed given increased incidence of gastric cancer aging population. Methods: used NIS database identify all admitted US hospitals for gastrectomy from 2005-2010. Outcomes and younger were compared. Results: identified 9455 pts, median was 68; 3022 (32%) group (age 75) 6433 (68%) 18–74. Elderly had more major...
e16505 Background: Docetaxel is a chemotherapeutic agent indicated for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This study aims to evaluate the efficacy and safety data of docetaxel-based therapy in pts hormone-sensitive (mHSPC) mCRPC. Methods: PubMed ASCO databases were searched randomized control trials (RCTs) treatment mHSPC mCRPC through December 31st, 2015. Study endpoints included overall survival (OS), progression free survival/failure-free...
e20600 Background: Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of advanced NSCLC and SCLC. The populations in clinical trials generally were composed patients (pts) with excellent performance status (PS), a minimal number prior lines therapy, no history (h/o) autoimmune disease (AD). aim this retrospective study was to investigate predictors survival less fit more heavily pretreated lung cancer pts at our institution. Methods: Medical records who started...
8027 Background: Escalating doses of Vel with high dose Mel (Rowley, ASH 2009) and escalating Thal + (Hong, 2012) as ASCT conditioning in pts advanced MM were previously reported. We performed an updated analysis these studies. Methods: either disease progression or less than PR (MelVel study) CR (MelVelThal after a prior enrolled 2 single arm In MelVel, was escalated steps 1, 1.3 1.6mg/m2 (3x3 design) on day (d) -4 -1 200 mg/m2 given d -2. MelVelThal, 600, 800 1000 mg daily -5 through...